TABLE 3.

Relebactam and imipenem concentrations in ELF after multiple-dose administration of relebactam at 250 mg with imipenem-cilastatin at 500 mg in healthy subjects^a

Time (h)	Relebactam concn in ELF (μM)		Imipenem concn in ELF (μM)		Relebactam/imipenem concn ratio
	GMb	95% CIc	GM	95% CI	GMRd	90% CI
0.5	14.93	9.89, 22.53	32.09	21.26, 48.44	0.47	0.45, 0.49
1	10.93	7.24, 16.50	20.27	13.43, 30.59	0.54	0.52, 0.56
1.5	9.49	6.29, 14.32	16.47	10.92, 24.87	0.58	0.55, 0.60
3	4.27	2.83, 6.45	5.99	3.97, 9.04	0.71	0.68, 0.74

^aData are for four subjects at each time point.

^bGM, geometric mean, which is the back-transformed least-squares mean from the linear mixed-effects model performed on the natural log-transformed values with for compound (MK and IPM), time (4 levels), and the compound-by-time interaction as fixed effects and subjects as a random effect.

^cCI, confidence interval.

^dGMR, geometric mean ratio.